Divi's Lab.
Divis Laboratories Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #54 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
The company targets double-digit growth in revenue and sales consistently, as stated by both Dr. Divi’s Laboratories aims for consistent double-digit revenue growth driven by a healthy product mix and diversified customer base.
From Divi's Lab.'s Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- The company targets double-digit growth in revenue and sales consistently, as stated by both Dr. Kiran S. Divi and Nilima Prasad Divi.
- Growth is driven by ongoing validation and commercialization of new projects, including peptides and small molecules.
- Several validation batches are continuing, with multiple projects in different development stages expected to contribute revenue gradually.
- The launch of commercial volumes post-regulatory approvals will positively impact growth, though timelines depend on approvals.
- Expansion projects (capex of around ₹2,000 crores, 70% incurred) will support capacity additions and future growth.
- Growth assumes a healthy product mix without over-reliance on any single product or customer.
2 more points from Divi's Lab.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Divi's Lab. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Divi’s Laboratories has three major ongoing capex projects nearing completion, with about 70% of the ₹2,000 crores investment capitalized so far (Page 13).
- These projects include capacity expansions supporting validation batches and future commercial production, with one related long-term contract negotiation in the contrast media segment (Page 9, 13, 14).
- Significant capacity expansions are underway in peptide manufacturing, including installing multiple 3,000-liter solid-phase peptide synthesis (SPPS) lines to capture future opportunities (Page 13).
- Unit 3 plays a strategic role by supporting backward integration, pre-chemistry operations, and enabling efficient capacity utilization through phased manufacturing transfers (Page 5, 14).
2 more points from Divi's Lab.'s call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Divi's Lab. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Divi's Laboratories is currently engaged in validation batches for several projects, including three major dedicated capex projects involving different products.
- Due to confidentiality and CDAs, specific details on order book size, product names, or quantities cannot be disclosed.
- The company has supplied validation quantities for about 4 new DMFs as part of their generic portfolio, which are undergoing customer qualification.
- Several projects are in various pipeline stages: clinical studies, pre-validation, and validations.
- Commercial supplies will only start after customer qualifications and regulatory approvals.
- The firm expects a double-digit growth in revenue, supported by ongoing and upcoming validations leading to commercial orders.
2 more points from Divi's Lab.'s call on order book
Create a free account to keep reading this call
Divi's Lab. — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.8K Cr, net profit ₹751 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Divi's Lab.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Divi's Lab. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Divi's Lab. Q1 FY27 results?
The company targets double-digit growth in revenue and sales consistently, as stated by both Dr. Divi’s Laboratories aims for consistent double-digit revenue growth driven by a healthy product mix and diversified customer base.
What is Divi's Lab. share price analysis?
Divi's Lab. currently shows a below-average growth signal. The stock trades at a P/E of 83.5 with a market cap of ₹248,877 Cr. Investors should review the full earnings analysis for detailed insights.
Is Divi's Lab. planning capital expenditure?
Divi’s Laboratories has three major ongoing capex projects nearing completion, with about 70% of the ₹2,000 crores investment capitalized so far (Page 13).
Keep Divi's Lab. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.